P. Barclay

发表

EFFECTS OF UK 69 578: A NOVEL ATRIOPEPTIDASE INHIBITOR

D. Northridge, S. Dilly, Henry G Dargie, 1989, The Lancet.

Neutral endopeptidase regulates C-type natriuretic peptide metabolism but does not potentiate its bioactivity in vivo.

J. Burnett, A. Clavell, R. Brandt, 1997, Hypertension.

The role of neutral endopeptidase in dogs with evolving congestive heart failure.

K. Margulies, J. Burnett, P. Barclay, 1995, Circulation.

Renal effects of neutral endopeptidase inhibition in euvolemic and hypervolemic rats.

J. Scott, N. Shepperson, P. Barclay, 1993, European journal of pharmacology.

UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic.

K. James, M. Wythes, N. Terrett, 1989, Biochemical and biophysical research communications.

Inhibition of neutral endopeptidase (EC 3.4.24.11) leads to an atrial natriuretic factor-mediated natriuretic, diuretic and antihypertensive response in rodents.

J. Bennett, N. Shepperson, P. Barclay, 1991, Clinical science.

The atriopeptidase inhibitor (+/-) candoxatrilat reduces the clearance of atrial natriuretic factor in both intact and nephrectomized rats: evidence for an extrarenal site of action.

J. Bennett, N. Shepperson, P. Barclay, 1991, Biochemical pharmacology.

Atriopeptidase inhibitors a novel class of drugs that raises levels of endogenous atrial natriuretic factor the preclinical pharmacology of uk 69578

P. Ellis, P. Barclay, C. J. Peters, 1989 .

The pharmacokinetics of 125I-atrial natriuretic factor in anaesthetized rats. Effects of neutral endopeptidase inhibition with candoxatrilat and of ANF-C receptor blockade.

J. Bennett, N. Shepperson, P. Greengrass, 1992, Biochemical pharmacology.

Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH.

P. Touraine, I. Kourides, R. Abs, 2009, European journal of endocrinology.

The influence of acetazolamide and amlodipine on the intracellular sodium content of rat proximal tubular cells

M. J. Newman, E. Johns, P. S. Wong, 1994, British journal of pharmacology.

Labelling of the cytoplasmic domains of ovine rhodopsin with hydrophilic chemical probes.

J. Findlay, P. Barclay, 1984, The Biochemical journal.

The natriuretic and diuretic responses to the atriopeptidase inhibitor UK-69,578 in volume expanded rats.

J. Bennett, N. Shepperson, J. Danilewicz, 1989, British journal of pharmacology.

Inhibition of thermolysin and neutral endopeptidase 24.11 by a novel glutaramide derivative: X-ray structure determination of the thermolysin-inhibitor complex.

D. R. Holland, B. Matthews, K. James, 1994, Biochemistry.

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a New Cholesteryl Ester Transfer Protein Inhibitor in Healthy Human Subjects

J. Mancuso, R. Wolk, R. Clark, 2009, Clinical pharmacology and therapeutics.

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.

Bo Feng, David B Duignan, Bruce Auerbach, 2011, Bioorganic & medicinal chemistry letters.

The structure of mammalian rod opsins

D. Pappin, J. Findlay, M. Davison, 1984, Vision Research.

Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH.

P. Touraine, I. Kourides, R. Abs, 2009, European journal of endocrinology.

Inhibitory potencies of UK-69 578 and thiorphan

J. Danilewicz, P. Barclay, G. Samuels, 1990, The Lancet.

The natriuretic and diuretic efficacy of atriopeptidase inhibitors following intravenous and oral administration.

N. Shepperson, P. Ellis, P. Barclay, 1989, British journal of pharmacology.